Business
Notice of Interim Results
Arecor Therapeutics PLC will release its interim results for the six months ending June 30, 2025, on Thursday, September 25, 2025. A webcast for analysts and institutional investors will be hosted by the Chief Executive Officer and Chief Financial Officer at 3pm UK time on the same day. The company's lead product is AT278, an ultra-concentrated (500U/mL) ultra-rapid acting insulin. Arecor is also developing a novel oral delivery platform for peptides targeting the obesity and diabetes markets. The company is listed on AIM (AIM: AREC). Disclaimer*
About this update from Arecor Therapeutics Plc
[{"type":"text","content":"\n\n\n\n\n\n\n\nArecor Therapeutics plc\n(\"Arecor\" or the \"Company\")\n \nNotice of Interim Results\n \nCambridge, UK, 24 September 2025: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company focused on drug development and delivery in diabetes and other cardiometabolic diseases, will announce its interim results for the six months ended 30 June on Thursday 25 September 2025.\nDr Sarah Howell, Chief Executive Officer, and David Ellam, Chief Financial Officer, will host a webcast for analysts and institutional investors at 3pm UK time on Thursday 25 September 2025. To register, please contact [email protected]. A copy of the interim results presentation will be released after the meeting on the Company website at www.arecor.com. \n \n-ENDS- \nFor more information, please contact:\n \n\n\n\n\nArecor Therapeutics plc \nDr Sarah Howell, Chief Executive Officer\nDavid Ellam, Chief Financial Officer\n\n\n+44 (0) 1223 426060\[email protected] \n\n\n\n\n \n\n\n \n\n\n\n\nSinger Capital Markets Advisory LLP (NOMAD and Broker)\n\n\n+44 (0) 20 7496 3000\n\n\n\n\nPhil Davies, Sam Butcher\n\n\n \n\n\n\n\n \n\n\n \n\n\n\n\nVigo Consulting Melanie Toyne-Sewell, Rozi Morris\n\n\n+44 (0) 20 7390 0230\[email protected] \n\n\n\n\n\n\n\n \n\n\n\n\n \nNotes to Editors\n \nAbout Arecor\nArecor Therapeutics plc is a clinical stage biopharmaceutical company focused on drug development and delivery in diabetes and other cardiometabolic diseases. The Company is applying its proprietary technology platform, Arestat™, to develop a portfolio of proprietary products, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. Its lead product is AT278, the only ultra-concentrated (500U/mL) ultra-rapid acting insulin which is being co-developed with a US Automated Insulin Delivery pump device partner. Arecor is also developing a novel oral delivery platform for peptides (e.g. GLP-1 receptor agonists) targeting the obesity and diabetes markets. The Company is listed on AIM (AIM: AREC) and is based in Cambridge, UK. For further details please see www.arecor.com\n \n\n","length":6397,"tagName":"div"}]